I am Miranda from Shenzhen, China, and I’m delighted to meet everyone on this flawless forum. I work as a technician at Uray Biotech, mainly developing enzymes for Sanger sequencing, including BDT, POP7, Hi-Di, and others. My greatest achievement so far has been developing a BDT specifically for hairpin (HP) structures—it can easily handle all HP samples during sequencing. I’m very happy to discuss with everyone the various challenges and issues encountered in Sanger sequencing.
-
NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...Yesterday, 06:46 AM -
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM